CCEL - Cryo-Cell International, Inc. Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Corporate emblem and logo of Cryo-Cell International Inc (CCEL)

Cryo-Cell International (CCEL) generates revenue from long-term biobanking fees, which ensures a predictable cash flow and eliminates liquidity shortages. The company's environmental development vector relies on upgrading cryochamber insulation and transitioning to green energy. The current EV/EBITDA ratio stands at 29.80. The asset's price trajectory shown below confirms the effectiveness of management's strategy to implement GMP standards and expand cell therapy.

Cryo-Cell - CCEL Enterprise Value to EBITDA Ratio (period 11/23/2025 - 11/12/2026)

CCEL (cryo-cell.com): analytical breakdowns and indicator data

- market price and analyst price targets:
Price Chart Cryo-Cell International, Inc.|CCEL - Price Target Chart
- market capitalization statistics:
Market Value CCEL|CCEL - Company Buyout Price
- book value of equity indicators:
Book Value per Share Cryo-Cell International|CCEL - Company Net Assets|Market Value to Book Value Ratio cryo-cell.com|CCEL - Aggregate Asset Value
- company liabilities and liquidity data:
Total Debt to Equity Ratio Cryo-Cell International|CCEL - Long-Term Liabilities to Capital|Short-Term Debt to Equity Cryo-Cell International, Inc.|CCEL - Company Cumulative Debt|Debt to Book Value CCEL|CCEL - Long-Term Indebtedness|Company Short-Term Debts Cryo-Cell International|Quick Ratio cryo-cell.com
- financial results and valuation multiples details:
CCEL - Company Net Income|Expected Profit Cryo-Cell International|CCEL - Price to Earnings Ratio|Future Price to Earnings Cryo-Cell International, Inc.|CCEL - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio CCEL|CCEL - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Cryo-Cell International|CCEL - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months cryo-cell.com|CCEL - Earnings per share growth this year|Expected earnings per share growth for next year Cryo-Cell International
Initial company analysis:Cryo-Cell International Inc (CCEL)
Manufactured products of Cryo-Cell International, Inc.

Fundamental asset screening requires a precise determination of business value relative to its operating profit before depreciation, interest, and taxes. By analyzing the EV/EBITDA multiple, an investor assesses the real market weight of Cryo-Cell International (CCEL) accounting for debt, which is further supported by the stability of costs for retaining highly qualified biochemists and the absence of labor shortages.

Main competitors

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Mesoblast Corp MESO|Lineage Corp - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SRZN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio FibroBiologics, Inc. FBLG|LGVN: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio BioRestorative Therapies, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Creative Medical Technology Holdings, Inc.